En samlet analyse af fem effektivitetsundersøgelser *, viste et punktestimat på 71, 4% (95% CI:
A pooled analysis of five efficacy studies*, showed a 71.4% (95% CI:20.1;91.1) efficacy against severe rotavirus gastro-enteritis (Vesikari score ≥11) caused by rotavirus G2P[4] type during the first year of life.